期刊文献+

抗癫疒间肽纳米粒的制备及体外释药性能的研究 被引量:1

Preparation of anti-epilepsy peptide nanoparticles and investigation of the drug releasing characteristic in vitro
下载PDF
导出
摘要 目的制备抗癫疒间肽纳米粒,并研究其体外释药性能。方法选用聚乙二醇-聚乳酸-聚乙醇酸嵌段共聚物为载体,采用复乳-溶剂挥发法制备抗癫疒间肽纳米粒,以包封率、载药量等指标优化制备工艺,并研究纳米粒体外释药性能。结果抗癫疒间肽纳米粒外观呈圆形或类圆形,平均粒径为(100.2±2.45)nm,包封率和载药量分别为(64.46±1.34)%和(4.73±0.32)%,体外释药呈现缓释和突释两个阶段,符合Weibull方程。结论建立的制备工艺简便可行,得到的抗癫疒间肽纳米粒包封率和载药量较高,粒径小,体外释药具有明显的缓释特征。 Objective To prepare anti-epilepsy peptide nanoparticles and evaluate its release characteristics in vitr. Methods Anti-epilepsy peptide nanoparticles were prepared by emulsion/solvent evaporation method and poly (ethylene glycol)-poly(lactide acid)-poly(glycolic acid)copolymer was used as carrier material. Encapsulation effi-ciency and drug loading were used to optimize the technique and evaluate its release characteristics in vitro. Results The appearance of all anti-epilepsy peptide nanoparticles were round or similar. The mean particle size,encapsulation efficiency and drug loading of anti-epilepsy peptide nanoparticles were ( 100. 2 ± 2. 45 ) nm, ( 64. 46 ± 1. 34 )% and (4. 73 ± 0. 32)%respectively. The drug release from nanoparticles appeared consisting of two phases with initial burst release and sustained-release in vitro,and the release rule accorded with Weibull equation. Conclusion The preparation technics is simple and feasible,and the obtained anti-epilepsy peptide nanoparticles has high encapsulation efficiency, high drug loading,small mean diameter and the drug releasing characteristic is sustained in vitro.
出处 《实用药物与临床》 CAS 2014年第11期1445-1448,共4页 Practical Pharmacy and Clinical Remedies
基金 浙江省医药卫生科技计划(2011KYB144) 台州学院青年基金(2012QN33)
关键词 抗癫疒间肽 纳米粒 体外释药 Anti-epilepsy peptide Nanoparticles Drug releasing characteristic in vitro
  • 相关文献

参考文献8

  • 1王宗仁,邵中军,李晶华,行利,马静,龙铟,张磊,赵艳玲.抗癫痫肽重组腺伴病毒载体的构建及鉴定[J].中草药,2005,36(12):1844-1846. 被引量:4
  • 2Yu L, Ci T, Zhou S, et al. The thermogelling PLGA-PEG-PL- GA block copolymer as a sustained release matrix of doxorubi- cin [J]. Biomater Sci,2013,4 (10) :411-420.
  • 3Lii JM, Wang X, Matin-Muller C, et al. Current advances in re- search and clinical applications of PLGA-based nanotechnology E J 1. Expert Rev Mol Diagn, 2009,9 ( 4 ) : 325-341.
  • 4Li M, Panagi Z, Avgoustakis K, et al. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content [J]. Int J Nanomedicine ,2012, (7) :1345-1356.
  • 5Betancourt T, Byrne JD, Sunaryo N, et al. PEGylation strategies for active targeting of PLA/PLGA nanoparticles[J]. J Biomed Mater Res ,2009 ,91 ( 1 ) :263-276.
  • 6Joseph B ,George J. Scorpion toxins and its applications [J]. Int J Toxi Pharm Res,2012,4(3) :57-61.
  • 7Wang Z, Wang W, Shao Z, et al. Eukaryotic expression and purification of anti-epilepsy peptide of Buthus martensii Karsch and its protein interactions [J ]. Mol Cell Biochem, 2009,330 (1-2) :97-104.
  • 8Wen JG, Guo TT, Zhu HY, et al. Preparation and optimization of PEG-PLGA loaded with vincristine sulfate and its in vitr re- lease [J]. J Bioequiv Availab ,2011,3 ( 9 ) : 211-214.

二级参考文献1

共引文献3

同被引文献12

  • 1Esatbeyoglu T, Huebbe P, Ernst IM, et al. Curcumin from mol- ecule to biological function [ J ]. Angew Chem Int Ed Engl, 2012,51 (22) :5308-5332.
  • 2Anuchapreeda S, Thanarattanakom P, Sittipreechacham S, et al. Inhibitory effect of curcumin on MDRI gene expression in patient leukemic cells [ J ]. Arch Pharm Res, 2006,29 ( l0 ) : 866-873.
  • 3Sa G,Das T. Anti-cancer effects of curcumin:cycle of life and death [ J ]. Cell Div,2008,10 (3) : 14.
  • 4Dasi F, Martinez RP, March JA, et al. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer[J ]. Ann N Y Acad Sci,2006, 1075 ( 1 ) :204-210.
  • 5Anand P, Kunnumakkara AB, Newman RA, et al. Bioavail- ability of curcumin : problems and promises [ J ]. MO1 Pbarrrt, 2007,4(6 ) :807-818.
  • 6Zhang P,Ling G,Pan X,et al. Novel rtanostructured lipid-dex- tran sulfate hybrid carders overcome tumor multidrug resist- mace of mitoxantrone hydrochloride [ J ]. Nanomedicine, 2012, 8 : 185-193.
  • 7Messerschmidt SK, Musyanovych A, Altvater M, et al. Targe- ted lipid-coated nanoparticles: delivery of tumor necrosis fac- tor-functionalized particles to tumor cells[ J]. J Controlled Re- lease,2009,137( 1 ) :69-77.
  • 8Van Schooneveld MM, Vucic E, Koole R, et al. Improved bio-compatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating : a multimodality investigation [ J ]. Nano Letter,2008,8 (8) :2517-2525.
  • 9Liu MX, Dong J, Yang Y J, et al. Characterization and release of triptolide-loaded poly ( D, L-lactic acid) nanoparticles [ J ]. Eur Pol,2005,41 (2) :375-382.
  • 10霍红梅,张利元,江家贵,朱旬.姜黄素抑制乳腺癌MCF-7细胞增殖及其相关的氧化应激机制[J].中国肿瘤生物治疗杂志,2009,16(5):490-493. 被引量:13

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部